<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02893423</url>
  </required_header>
  <id_info>
    <org_study_id>Study # 13/01/VA01</org_study_id>
    <nct_id>NCT02893423</nct_id>
  </id_info>
  <brief_title>Ropivacaine Transversus Abdominis Plane Blocks for Cesarean Section Analgesia</brief_title>
  <acronym>TAPROPI</acronym>
  <official_title>The Dose Dependent Effect of Ropivacaine Transversus Abdominis Plane Blocks on Postoperative Analgesia After Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maimonides Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maimonides Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With this research the investigators hope to determine the lowest dose of ropivacaine used in
      transversus abdominis plane (TAP) blocks that can effectively treat pain in women after
      cesarean section (c-section).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With this research the investigators hope to determine the lowest dose of ropivacaine used in
      transversus abdominis plane (TAP) blocks that can effectively treat pain in women after
      cesarean section (c-section). The TAP is a space between the muscle layers of the abdominal
      wall that houses nerves supplying the abdominal skin. The investigators will inject the local
      anesthetic ropivacaine into this space to freeze these nerves and prevent pain following
      c-section. The investigators will compare three different doses of ropivacaine (0.5%, 0.25%,
      0%) to determine the lowest dose that controls pain with the fewest side effects.
      Participants in this study will receive 0.5% (Group 1), 0.25% (Group 2), or 0% (Group 3)
      ropivacaine TAP blocks to control pain after c-section. At 2, 6, 12, 24, and 48 hours after
      cesarean section visual analog pain scores (VAS) for pain on movement, pain at rest, and pain
      with cough will be collected along with the time to first postoperative analgesic request,
      patient satisfaction scores, and patient demographics. The analgesic regimen will be
      considered effective if it provides lower average visual analog scores for pain with
      movement. Secondary outcomes will be higher patient satisfaction, better pain control, fewer
      postoperative analgesic requests, and fewer side effects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>POSTOPERATIVE PAIN</measure>
    <time_frame>48 hours</time_frame>
    <description>Severity of postoperative pain will be assessed using(VAS) scale</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>postoperative rescue analgesics</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Frequency of rescue analgesics request in the postoperative period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient satisfaction</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Overall patient satisfaction will be assessed using the VAS score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>POSTOPERATIVE NAUSEA AND VOMITING</measure>
    <time_frame>up to 48 hours</time_frame>
    <description>Severity of postoperative nausea and vomiting will be assessed using VAS score</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group 1 - 0.5% Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.5% Ropivacaine for the TAP block Procedure: Ultrasound guided TAP BLOCK Drug: 0.5% ropivacaine 20ml of 0.5% ropivacaine is used to perform the TAP block Other Names: •Naropin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - 0.25% Ropivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive 0.25% for the TAP block Procedure: ULTRASOUND GUIDED TAP BLOCK Drug: 0.25% ropivacaine 20ml of 0.25% ropivacaine is used to perform the TAP block Other Names: •Naropin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - No Tap Block</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will not receive a TAP BLOCK</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients</description>
    <arm_group_label>Group 1 - 0.5% Ropivacaine</arm_group_label>
    <arm_group_label>Group 2 - 0.25% Ropivacaine</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant patients undergoing elective c-section

        Exclusion criteria:

          -  Allergy to local anesthetics

          -  Contraindication to tap blocks
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KALPANA TYAGARAJ, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MAIMONIDES MEDICAL CENTER, 4802, 10TH AVENUE, BROOKLYN, NY-11219</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KALPANA TYAGARAJ, MD</last_name>
    <phone>718-283-1753</phone>
    <email>ktyagaraj@maimonidesmed.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>dennis feierman, MD,PhD</last_name>
    <phone>718-283-7611</phone>
    <email>dfeierman@maimonidesmed.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Maimonides Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kalpana Tyagaraj, MD</last_name>
      <phone>718-283-1753</phone>
      <phone_ext>1753</phone_ext>
      <email>Kalpana_Tyagaraj@msn.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2016</study_first_posted>
  <last_update_submitted>April 7, 2018</last_update_submitted>
  <last_update_submitted_qc>April 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Maimonides Medical Center</investigator_affiliation>
    <investigator_full_name>kalpana tyagaraj</investigator_full_name>
    <investigator_title>Residency Program Director</investigator_title>
  </responsible_party>
  <keyword>Ropivacaine</keyword>
  <keyword>C-Section Analgesia</keyword>
  <keyword>Tap Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

